- Trials with a EudraCT protocol (19)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
19 result(s) found for: Rod cone dystrophy.
Displaying page 1 of 1.
EudraCT Number: 2008-004561-26 | Sponsor Protocol Number: 1080/08 | Start Date*: 2009-06-01 | ||||||||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | ||||||||||||||||||
Full Title: Inner Retinal Dysfunction of the Cone System in Inherited Photoreceptor Degenerations: A Study of Disease Sequence and Assessment of Novel Therapeutic Strategies. | ||||||||||||||||||
Medical condition: retinitis pigmentosa | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002729-74 | Sponsor Protocol Number: PQ-421a-003 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:ProQR Therapeutics IV B.V. | |||||||||||||
Full Title: A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of t... | |||||||||||||
Medical condition: Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) NO (Completed) DK (Completed) NL (Ongoing) IT (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002728-19 | Sponsor Protocol Number: PQ-421a-004 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:ProQR Therapeutics IV B.V. | |||||||||||||
Full Title: A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of t... | |||||||||||||
Medical condition: Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) NO (Prematurely Ended) DK (Completed) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000425-31 | Sponsor Protocol Number: MGT010 | Start Date*: 2018-08-30 | |||||||||||
Sponsor Name:MeiraGTx UK II Ltd | |||||||||||||
Full Title: Long term follow-up study of participants following an open label, multicentre, Phase I/II dose escalation trial of a recombinant adeno-associated virus vector (AAV2/5-hRKp.RPGR) for gene therapy o... | |||||||||||||
Medical condition: X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002523-28 | Sponsor Protocol Number: KHAK1001 | Start Date*: 2016-09-16 | |||||||||||
Sponsor Name:Moorfields Eye Hospital | |||||||||||||
Full Title: A Pilot Study Evaluating the Effect of Intravitreal Fluocinolone Acetonide (0.19mg) in Patients with Retinitis Pigmentosa | |||||||||||||
Medical condition: Retinitis Pigmetosa. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002696-10 | Sponsor Protocol Number: CCPK850X2202 | Start Date*: 2018-05-09 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: An open-label first-in-human single ascending dose study to explore the safety, tolerability and efficacy of subretinal administration of CPK850 gene therapy in patients with retinitis pigmentosa c... | |||||||||||||
Medical condition: retinitis pigmentosa caused by biallelic mutations in the RLBP1 gene | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003852-60 | Sponsor Protocol Number: NSR-RPGR-01 | Start Date*: 2017-01-09 | |||||||||||
Sponsor Name:NightstaRx Limited | |||||||||||||
Full Title: A Dose Escalation (Phase 1), and Dose Expansion (Phase 2/3) Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV8) Encoding Retinitis... | |||||||||||||
Medical condition: X-Linked retinitis pigmentosa (XLRP) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002433-38 | Sponsor Protocol Number: PQ-421a-001 | Start Date*: 2019-02-15 | |||||||||||
Sponsor Name:ProQR Therapeutics | |||||||||||||
Full Title: A First-in-Human Study to Evaluate the Safety and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene | |||||||||||||
Medical condition: Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000457-53 | Sponsor Protocol Number: STREAM | Start Date*: 2019-02-08 | |||||||||||
Sponsor Name:CECS/I-STEM | |||||||||||||
Full Title: A phase 1/2, open-label, safety, tolerability and preliminary efficacy study of implantation into one eye of hESC-derived RPE (Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE)) i... | |||||||||||||
Medical condition: Retinitis Pigmentosa due to monogenic mutation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002873-88 | Sponsor Protocol Number: MGT-RPGR-021 | Start Date*: 2022-07-19 | |||||||||||
Sponsor Name:MeiraGTx UK II Limited | |||||||||||||
Full Title: Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene | |||||||||||||
Medical condition: X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) NL (Ongoing) BE (Completed) ES (Ongoing) FR (Completed) DK (Completed) DE (Prematurely Ended) IT (Completed) Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002255-37 | Sponsor Protocol Number: MGT-RPGR-022 | Start Date*: 2022-05-26 | |||||||||||
Sponsor Name:MeiraGTx UK II Limited | |||||||||||||
Full Title: Phase 3 Follow-up Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene | |||||||||||||
Medical condition: X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) NL (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) DK (Trial now transitioned) DE (Prematurely Ended) IT (Trial now transitioned) Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003723-65 | Sponsor Protocol Number: MICM1014 | Start Date*: 2016-01-12 | |||||||||||
Sponsor Name:Moorfields Eye Hospital | |||||||||||||
Full Title: Aflibercept (Eylea®) for macular oedema associated with underlying Retinitis Pigmentosa (AMOUR) | |||||||||||||
Medical condition: Retinitis Pigmentosa associated Cystoid Macular Oedema | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000385-22 | Sponsor Protocol Number: RF-2010-2318561 | Start Date*: 2014-10-07 | ||||||||||||||||
Sponsor Name:Ospedale San Raffaele di Milano | ||||||||||||||||||
Full Title: Nerve Growth Factor eye drops as a novel treatment for vision loss in patients with Retinitis Pigmentosa: from preclinical to clinical Phase II trial. | ||||||||||||||||||
Medical condition: Retinitis pigmentosa with cystoid macular edema | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003104-42 | Sponsor Protocol Number: NSR-CHM-OS2(273CH201) | Start Date*: 2018-01-05 | ||||||||||||||||
Sponsor Name:NightstaRx Ltd (A Biogen Company) | ||||||||||||||||||
Full Title: A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects with Choroideremia Previously Treated with Adeno-Associated Viral Vector Encoding Rab Escort Prot... | ||||||||||||||||||
Medical condition: Choroideremia (CHM) X-Linked Retinitis Pigmentosa (XLRP) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) FI (Completed) FR (Trial now transitioned) DK (Completed) NL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004214-42 | Sponsor Protocol Number: RETIRD02 | Start Date*: 2012-09-03 | ||||||||||||||||
Sponsor Name:QLT Inc. | ||||||||||||||||||
Full Title: An Open-Label Study to Evaluate the Effects of Repeated Treatments of Oral QLT091001 on Safety and Vision Outcome in Subjects with Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due ... | ||||||||||||||||||
Medical condition: Leber Congenital Amaurosis Retinitis pigmentosa | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) DE (Completed) NL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005393-22 | Sponsor Protocol Number: RETIRD04 | Start Date*: 2016-11-03 | ||||||||||||||||
Sponsor Name:QLT Inc. | ||||||||||||||||||
Full Title: A Study of the Efficacy and Safety of QLT091001 in Subjects with Inherited Retinal Disease (IRD) Caused by Mutation in Retinal Pigment Epithelium Protein 65 (RPE65) or Lecithin:Retinol Acyltransfer... | ||||||||||||||||||
Medical condition: Inherited retinal disease (IRD) phenotypically diagnosed as Leber congenital amaurosis (LCA) or retinitis pigmentosa (RP) caused by mutations in the retinal pigment epithelium protein 65 (RPE65) or... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Prematurely Ended) NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004058-11 | Sponsor Protocol Number: RM-493-023 | Start Date*: Information not available in EudraCT |
Sponsor Name:Rhythm Pharmaceuticals, Inc. | ||
Full Title: A Phase 3 trial of Setmelanotide (RM-493), a Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström syndrome (AS) Patients with Moderate to Severe Obesity | ||
Medical condition: Obesity and hyperphagia in patients with Bardet-Biedl Syndrome or Alström syndrome | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) ES (Completed) GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2006-001571-37 | Sponsor Protocol Number: AAV2/2-hRPE65p-hRPE65 | Start Date*: 2006-12-14 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: AN OPEN-LABEL DOSE ESCALATION STUDY OF AN ADENO-ASSOCIATED VIRUS VECTOR (AAV2/2-hRPE65p-hRPE65) FOR GENE THERAPY OF SEVERE EARLY-ONSET RETINAL DEGENERATION | |||||||||||||
Medical condition: The condition to be investigated is severe early-onset inherited retinal degeneration due to defects in the gene encoding RPE65 | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023111-34 | Sponsor Protocol Number: SG1/001/10 | Start Date*: 2011-07-18 |
Sponsor Name:Oxford BioMedica (UK) Ltd | ||
Full Title: A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected StarGen, Administered to Patients with Stargardt's Macular Degeneration. | ||
Medical condition: Stargardt Macular Dystrophy, also known as fundus flavimaculatus or Stargardt disease. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) NL (Not Authorised) IT (Prematurely Ended) Outside EU/EEA | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
